Fog City Capital

Ad-Lib is a digital creative tech and service business. The only UK based Double Click Creative Marketing Partner, We are a tech business that can help transform your online creative ability! We work with both Doubleclick and Facebook to improve the deployment of digital creative. We dont buy media, we just deliver excellent, optimised creative. - Dynamic Video offering - Integration with Facebook and Doubleclcick - A/B testing - Optimisation algorythem - Full preview solution - No double ad serving - Time savings of up to 46% - Performance uplift of up to 80% - Full service offering provided

Ad-Lib is a digital creative tech and service business. The only UK based Double Click Creative Marketing Partner, We are a tech business that can help transform your online creative ability! We work with both Doubleclick and Facebook to improve the deployment of digital creative. We dont buy media, we just deliver excellent, optimised creative. - Dynamic Video offering - Integration with Facebook and Doubleclcick - A/B testing - Optimisation algorythem - Full preview solution - No double ad serving - Time savings of up to 46% - Performance uplift of up to 80% - Full service offering provided

Visual IQ produces the world’s most powerful cross channel marketing attribution software products. As a pioneer in the space, the company has been offering products since 2006. Its SaaS-based IQ Intelligence Suite reveals cross channel performance insights hidden deep within companies’ marketing data, providing actionable recommendations and optimized media plans to improve marketing effectiveness. These recommendations enable marketers and agencies to adjust their advertising strategies and tactics to significantly increase marketing ROI across their entire marketing mix – both online and offline. The functionality behind these products combines a powerful, user-friendly interface with multi-dimensional fractional attribution science and predictive analytics that clearly and accurately show marketers where opportunities exist for improvement. Visual IQ was named a leader in cross channel attribution in 2014 by a leading market research firm, won The Drum's 2015 Digital Trading Award for Best Attribution Solution, won the 2014 ASPY Award for Best Data or Analytics Solution, and was a finalist in the Digital Analytics Association Excellence Awards in 2013, 2014 and 2015. The company is a member of the Advertising Technology, Data, Public Policy and CFO Councils of the IAB, as well as on the Standards Committee of the Digital Analytics Association.

Cianna Medical, Inc. is a women's health company dedicated to the innovative treatment of early-stage breast cancer. When diagnosed early, most women have the option to save their breast by choosing breast conservation therapy (BCT). Their mission is to make BCT available to more women, by developing new approaches to delivering follow-up radiation therapy.

Visual IQ produces the world’s most powerful cross channel marketing attribution software products. As a pioneer in the space, the company has been offering products since 2006. Its SaaS-based IQ Intelligence Suite reveals cross channel performance insights hidden deep within companies’ marketing data, providing actionable recommendations and optimized media plans to improve marketing effectiveness. These recommendations enable marketers and agencies to adjust their advertising strategies and tactics to significantly increase marketing ROI across their entire marketing mix – both online and offline. The functionality behind these products combines a powerful, user-friendly interface with multi-dimensional fractional attribution science and predictive analytics that clearly and accurately show marketers where opportunities exist for improvement. Visual IQ was named a leader in cross channel attribution in 2014 by a leading market research firm, won The Drum's 2015 Digital Trading Award for Best Attribution Solution, won the 2014 ASPY Award for Best Data or Analytics Solution, and was a finalist in the Digital Analytics Association Excellence Awards in 2013, 2014 and 2015. The company is a member of the Advertising Technology, Data, Public Policy and CFO Councils of the IAB, as well as on the Standards Committee of the Digital Analytics Association.

Cianna Medical, Inc. is a women's health company dedicated to the innovative treatment of early-stage breast cancer. When diagnosed early, most women have the option to save their breast by choosing breast conservation therapy (BCT). Their mission is to make BCT available to more women, by developing new approaches to delivering follow-up radiation therapy.

Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005.

Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

DexCom is a developer of glucose sensing technologies and focuses on these technologies. Founded in 1999, DexCom's roots stem from the pioneering 1967 research on implanted glucose sensors at the University of Wisconsin. DexCom started with a focus on creating an implantable Sensor that the body would not reject and that would perform for a long period of time.

Guava Technologies, Inc. develops, designs, and manufactures biotechnology and medical devices. Its products include HIV/AIDS monitoring, viacount cell counting and viability assay, antibody quantification assay, apoptosis assay suite, cell cycle assay, cytotoxicity assay, cell proliferation assay, and benchtop cell analysis systems. Guava Technologies also offers flow cytometry systems for cell biology research, drug discovery and development, and HIV/AIDS monitoring. It serves life science research, drug discovery and development, cell biology research, core flow cytometry, and clinical diagnostics markets. The company's products are used in cell counting/viability, antibody quantification, cell cycle and proliferation, cytotoxicity, and apoptosis applications. Guava Technologies, Inc. was founded in 1998 and is headquartered in Hayward, California. As of February 20, 2009, Guava Technologies, Inc. operates as a subsidiary of Millipore Corp.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.